常规实践中颈动脉内膜切除术后不同围手术期抗血小板治疗
基于德国全国法定质量保证数据库2010至2014年117973例择期颈动脉内膜切除术的回顾性分析,围手术期无抗血小板治疗者院内卒中或死亡风险显著高于阿司匹林单药治疗者(RR 1.21),双联抗血小板治疗较单药治疗死亡风险更低(RR 0.67)但需再次手术的继发性出血风险更高(RR 2.16)。
要点
- 围手术期无抗血小板治疗者卒中或死亡风险显著高于阿司匹林单药治疗者(RR 1.21,95%CI 1.04-1.42)。
- 双联抗血小板治疗较阿司匹林单药治疗死亡风险更低(RR 0.67,95%CI 0.51-0.88)。
- 双联抗血小板治疗较单药治疗需再次手术的继发性出血风险更高(RR 2.16,95%CI 1.88-2.50)。
核心结论
- 围手术期无任何抗血小板治疗者卒中或死亡风险显著高于阿司匹林单药治疗者,双联抗血小板治疗较阿司匹林单药治疗仅死亡风险更低但颈部出血风险更高。
- 围手术期抗血小板治疗与院内卒中及死亡风险降低显著相关。
- 作者认为需进一步研究评估单药与双联抗血小板治疗的风险获益比。
研究设计与样本
- 回顾性分析德国全国法定质量保证数据库2010至2014年117973例因无症状或症状性颈动脉狭窄行择期颈动脉内膜切除术的病例。
- 主要结局为出院前任何院内卒中或死亡,次要结局为任何大卒中或死亡、单纯死亡、卒中、心肌梗死、局部出血及任何局部并发症(颅神经麻痹、严重出血、急性闭塞)。
- 采用描述性统计和多水平多变量回归分析,以阿司匹林单药治疗为参照。
主要发现
- 患者以男性为主(68%),平均年龄71岁,症状性颈动脉狭窄占40%。
- 82.8%的患者围手术期接受阿司匹林单药治疗,2.7%接受其他血小板抑制剂,4.8%在双联抗血小板治疗下手术。
- 主要结局在所有患者中发生率为1.8%。
- 多水平多变量回归分析显示,无围手术期抗血小板治疗者卒中与死亡合计率显著高于单药治疗组(RR 1.21,95%CI 1.04-1.42),大卒中与死亡合计率亦然(RR 1.23,95%CI 1.02-1.48)。
- 双联抗血小板治疗与单纯死亡风险更低相关(RR 0.67,95%CI 0.51-0.88),但与需再次手术的继发性出血率显著更高相关(RR 2.16,95%CI 1.88-2.50)。
临床怎么用
- 作者认为需进一步研究评估单药与双联抗血小板治疗的风险获益比。
局限性
- 原文在结论中提出需进一步研究评估单药与双联抗血小板治疗的风险获益比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is currently no clear consensus regarding the optimal perioperative antiplatelet therapy regimen for carotid surgery. Therefore, associations between different antiplatelet therapies and the risk of stroke or death and perioperative complications after carotid endarterectomy on a national level in Germany were analyzed. METHODS: Overall, 117,973 elective carotid endarterectomies for asymptomatic or symptomatic carotid artery stenosis between 2010 and 2014 were included. Data were extracted from the statutory nationwide quality assurance database. The primary outcome was any in-hospital stroke or death until discharge from the hospital. Secondary outcomes were any major stroke or death, death alone, stroke, myocardial infarction, local bleeding, and any local complications (cranial nerve palsy, severe bleeding, acute occlusion). Descriptive statistics and multilevel multivariable regression analyses were applied. Single-agent therapy with aspirin was used as reference. RESULTS: Patients were predominantly male (68%), with a mean age of 71 years. Carotid stenosis was symptomatic in 40%. Of all patients, 82.8% were treated perioperatively by monotherapy with aspirin alone, 2.7% received other platelet inhibitors, and 4.8% of the patients were operated on under dual antiplatelet therapy. The primary outcome occurred in 1.8% of all patients. Multilevel multivariable regression analysis revealed that the combined stroke and death rate of patients with no perioperative antiplatelet therapy was significantly higher (risk ratio [RR], 1.21; 95% confidence interval [CI], 1.04-1.42) compared with the group of patients receiving monotherapy. The same was true for the major stroke and death rate (RR, 1.23; 95% CI, 1.02-1.48). In contrast, dual antiplatelet therapy was associated with a lower risk of death alone (RR, 0.67; 95% CI, 0.51-0.88) but with a significantly higher rate of secondary bleeding requiring reoperation (RR, 2.16; 95% CI, 1.88-2.50). CONCLUSIONS: This study shows that the risk of stroke or death was significantly higher in patients without any perioperative antiplatelet therapy. In contrast, dual antiplatelet therapy vs aspirin monotherapy was associated with a lower risk only of perioperative death but with a higher risk of neck bleeding until discharge. Perioperative antiplatelet therapy was significantly associated with a decreased in-hospital stroke and death risk. Further studies are needed to evaluate the risk-benefit ratio of single vs dual antiplatelet therapy.
引用
- Zimmermann A, Knappich C, Tsantilas P, et al. Different perioperative antiplatelet therapies for patients treated with carotid endarterectomy in routine practice. J Vasc Surg. 2018. PMID: 30064836. doi:10.1016/j.jvs.2018.01.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。